A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities

被引:86
作者
de Bruin, Gerjan [1 ]
Xin, Bo Tao [1 ]
Kraus, Marianne [2 ]
van der Stelt, Mario [1 ]
van der Marel, Gijsbert A. [1 ]
Kisselev, Alexei F. [3 ]
Driessen, Christoph [2 ]
Florea, Bogdan I. [1 ]
Overkleeft, Herman S. [1 ]
机构
[1] Leiden Univ, Leiden Inst Chem, Einsteinweg 55, NL-2333 CC Leiden, Netherlands
[2] Kantonsspital St Gallen, Dept Hematol & Oncol, CH-9007 St Gallen, Switzerland
[3] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Norris Cotton Canc Ctr, One Med Ctr Dr, Lebanon, NH 03756 USA
关键词
activity-based protein profiling; anticancer agents; fluorescent probes; inhibitors; proteasome; PROTEASOME INHIBITOR; IN-VIVO; MULTIPLE-MYELOMA; ANTIGEN PRESENTATION; CELL-LINES; BORTEZOMIB; SPECIFICITY; SUBSTRATE; SITES; IMMUNOPROTEASOMES;
D O I
10.1002/anie.201509092
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Proteasomes are therapeutic targets for various cancers and autoimmune diseases. Constitutively expressed proteasomes have three active sites, 1c, 2c, and 5c. Lymphoid tissues also express the immunoproteasome subunits 1i, 2i, and 5i. Rapid and simultaneous measurement of the activity of these catalytic subunits would assist in the discovery of new inhibitors, improve analysis of proteasome inhibitors in clinical trials, and simplify analysis of subunit expression. In this work, we present a cocktail of activity-based probes that enables simultaneous gel-based detection of all six catalytic human proteasome subunits. We used this cocktail to develop specific inhibitors for 1c, 2c, 5c, and 2i, to compare the active-site specificity of clinical proteasome inhibitors, and to demonstrate that many hematologic malignancies predominantly express immunoproteasomes. Furthermore, we show that selective and complete inhibition of 5i and 1i is cytotoxic to primary cells from acute lymphocytic leukemia (ALL) patients.
引用
收藏
页码:4199 / 4203
页数:5
相关论文
共 32 条
  • [1] The development of proteasome inhibitors as anticancer drugs
    Adams, J
    [J]. CANCER CELL, 2004, 5 (05) : 417 - 421
  • [2] Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells
    Altun, M
    Galardy, PJ
    Shringarpure, R
    Hideshima, T
    LeBlanc, R
    Anderson, KC
    Ploegh, HL
    Kessler, BM
    [J]. CANCER RESEARCH, 2005, 65 (17) : 7896 - 7901
  • [3] Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
    Berkers, CR
    Verdoes, M
    Lichtman, E
    Fiebiger, E
    Kessler, BM
    Anderson, KC
    Ploegh, HL
    Ovaa, H
    Galardy, PJ
    [J]. NATURE METHODS, 2005, 2 (05) : 357 - 362
  • [4] Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors
    Bogyo, M
    McMaster, JS
    Gaczynska, M
    Tortorella, D
    Goldberg, AL
    Ploegh, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) : 6629 - 6634
  • [5] Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
    Britton, Matthew
    Lucas, Marcella M.
    Downey, Sondra L.
    Screen, Michael
    Pletnev, Alexandre A.
    Verdoes, Martijn
    Tokhunts, Robert A.
    Amir, Omar
    Goddard, Ayrton L.
    Pelphrey, Philip M.
    Wright, Dennis L.
    Overkleeft, Herman S.
    Kisselev, Alexei F.
    [J]. CHEMISTRY & BIOLOGY, 2009, 16 (12): : 1278 - 1289
  • [6] A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
    Chauhan, Dharminder
    Singh, Ajita V.
    Aujay, Monette
    Kirk, Christopher J.
    Bandi, Madhavi
    Ciccarelli, Bryan
    Raje, Noopur
    Richardson, Paul
    Anderson, Kenneth C.
    [J]. BLOOD, 2010, 116 (23) : 4906 - 4915
  • [7] Syringolin A Selectively Labels the 20 S Proteasome in Murine EL4 and Wild-Type and Bortezomib-Adapted Leukaemic Cell Lines
    Clerc, Jerome
    Florea, Bogdan I.
    Kraus, Marianne
    Groll, Michael
    Huber, Robert
    Bachmann, Andre S.
    Dudler, Robert
    Driessen, Christoph
    Overkleeft, Herman S.
    Kaiser, Markus
    [J]. CHEMBIOCHEM, 2009, 10 (16) : 2638 - 2643
  • [8] Different proteasome subtypes in a single tissue exhibit different enzymatic properties
    Dahlmann, B
    Ruppert, T
    Kuehn, L
    Merforth, S
    Kloetzel, PM
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2000, 303 (05) : 643 - 653
  • [9] Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
    de Bruin, Gerjan
    Huber, Eva M.
    Xin, Bo-Tao
    van Rooden, Eva J.
    Al-Ayed, Karol
    Kim, Kyung-Bo
    Kisselev, Alexei F.
    Driessen, Christoph
    van der Stelt, Mario
    van der Marel, Gijsbert A.
    Groll, Michael
    Overkleeft, Herman S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (14) : 6197 - 6209
  • [10] Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
    Dou, Q. Ping
    Zonder, Jeffrey A.
    [J]. CURRENT CANCER DRUG TARGETS, 2014, 14 (06) : 517 - 536